Logo image of ACET

ADICET BIO INC (ACET) Stock Fundamental Analysis

NASDAQ:ACET - Nasdaq - US0070021086 - Common Stock - Currency: USD

0.7187  +0.02 (+2.67%)

After market: 0.735 +0.02 (+2.27%)

Fundamental Rating

3

Taking everything into account, ACET scores 3 out of 10 in our fundamental rating. ACET was compared to 561 industry peers in the Biotechnology industry. While ACET has a great health rating, there are worries on its profitability. ACET has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ACET has reported negative net income.
ACET had a negative operating cash flow in the past year.
ACET had negative earnings in each of the past 5 years.
In the past 5 years ACET always reported negative operating cash flow.
ACET Yearly Net Income VS EBIT VS OCF VS FCFACET Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

ACET has a Return On Assets of -47.93%. This is comparable to the rest of the industry: ACET outperforms 48.48% of its industry peers.
ACET has a better Return On Equity (-55.73%) than 61.32% of its industry peers.
Industry RankSector Rank
ROA -47.93%
ROE -55.73%
ROIC N/A
ROA(3y)-36.07%
ROA(5y)-46.69%
ROE(3y)-42.72%
ROE(5y)-63.13%
ROIC(3y)N/A
ROIC(5y)N/A
ACET Yearly ROA, ROE, ROICACET Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ACET does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACET Yearly Profit, Operating, Gross MarginsACET Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

More info and screens

7

2. Health

2.1 Basic Checks

ACET does not have a ROIC to compare to the WACC, probably because it is not profitable.
ACET has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ACET has been increased compared to 5 years ago.
There is no outstanding debt for ACET. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACET Yearly Shares OutstandingACET Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ACET Yearly Total Debt VS Total AssetsACET Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ACET has an Altman-Z score of -2.45. This is a bad value and indicates that ACET is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ACET (-2.45) is comparable to the rest of the industry.
ACET has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.45
ROIC/WACCN/A
WACC10.06%
ACET Yearly LT Debt VS Equity VS FCFACET Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 10.64 indicates that ACET has no problem at all paying its short term obligations.
ACET has a Current ratio of 10.64. This is amongst the best in the industry. ACET outperforms 81.11% of its industry peers.
A Quick Ratio of 10.64 indicates that ACET has no problem at all paying its short term obligations.
ACET has a better Quick ratio (10.64) than 81.11% of its industry peers.
Industry RankSector Rank
Current Ratio 10.64
Quick Ratio 10.64
ACET Yearly Current Assets VS Current LiabilitesACET Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

ACET shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.93%, which is quite impressive.
EPS 1Y (TTM)55.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ACET will show a small growth in Earnings Per Share. The EPS will grow by 4.50% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y10.29%
EPS Next 2Y10.57%
EPS Next 3Y10.33%
EPS Next 5Y4.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACET Yearly Revenue VS EstimatesACET Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
ACET Yearly EPS VS EstimatesACET Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACET reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ACET is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACET Price Earnings VS Forward Price EarningsACET Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACET Per share dataACET EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.57%
EPS Next 3Y10.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACET!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADICET BIO INC

NASDAQ:ACET (5/22/2025, 8:00:00 PM)

After market: 0.735 +0.02 (+2.27%)

0.7187

+0.02 (+2.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners55.53%
Inst Owner Change-2.26%
Ins Owners1.4%
Ins Owner Change-3.64%
Market Cap59.44M
Analysts82.86
Price Target6.53 (808.58%)
Short Float %2.96%
Short Ratio4.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.58%
Min EPS beat(2)2.1%
Max EPS beat(2)11.06%
EPS beat(4)4
Avg EPS beat(4)6.82%
Min EPS beat(4)2.1%
Max EPS beat(4)11.52%
EPS beat(8)4
Avg EPS beat(8)-23.82%
EPS beat(12)6
Avg EPS beat(12)-5.45%
EPS beat(16)9
Avg EPS beat(16)-2.63%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.28
P/tB 0.28
EV/EBITDA N/A
EPS(TTM)-1.3
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0
BVpS2.56
TBVpS2.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.93%
ROE -55.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.07%
ROA(5y)-46.69%
ROE(3y)-42.72%
ROE(5y)-63.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.47%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.64
Quick Ratio 10.64
Altman-Z -2.45
F-Score6
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)523.67%
Cap/Depr(5y)371.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
EPS Next Y10.29%
EPS Next 2Y10.57%
EPS Next 3Y10.33%
EPS Next 5Y4.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.96%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-76.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-133.08%
OCF growth 3YN/A
OCF growth 5YN/A